Vyvanse

It\'s called Vyvanse, and I have written about in the past.

Michael B. Laskoff: Giving Thanks for an Effective ADHD/ADD Treatment 2009

Shire markets Adderall XR, the top-selling hyperactivity treatment in the U.S., as well as Vyvanse, which is set to become Shire's key hyperactivity product once Adderall XR becomes generic on April 1.

Shire Buys the Right to Sell UCB's Hyperactivity Drug 2009

It\'s called Vyvanse, and I have written about in the past.

Michael B. Laskoff: Giving Thanks for an Effective ADHD/ADD Treatment 2009

It's called Vyvanse, and I have written about in the past.

Michael B. Laskoff: Giving Thanks for an Effective ADHD/ADD Treatment 2009

Since Adderall's last existing patent expired in 2009, Shire has focused on Vyvanse, which is growing more than twice as fast as the overall U.S. market for hyperactivity drugs as doctors switch prescriptions.

Reuters: Press Release 2011

So, instead of Adderall now, we have Adderall XR, or a cousin of Adderall called Vyvanse, which lasts that same 8 to 10 to maybe 12 hours.

A Mental Health Reader 2010

Vyvanse, which is approved to treat ADHD in children aged 6 to 12 years and in adults, is a therapeutically inactive prodrug, in which d-amphetamine is covalently bonded to l-lysine, and after oral ingestion it is converted to pharmacologically active d-amphetamine.

Health News from Medical News Today 2009

Vyvanse, which is approved to treat ADHD in children aged 6 to 12 years and in adults, is a therapeutically inactive prodrug, in which d-amphetamine is covalently bonded to l-lysine, and after oral ingestion it is converted to pharmacologically active d-amphetamine.

unknown title 2009

The drug is going generic in April and you want users to change over to the new version of this drug, called Vyvanse, sooner rather than later.

World of Psychology 2009

Shire, the U. K.'s third-largest drug maker by sales and market capitalization, makes other drugs to treat attention deficit hyperactivity disorder, such as Vyvanse and Daytrana, as well as human genetic therapies and gastrointestinal and renal disease treatments.

Shire Names 2007